In the South-East Asia Region and the Western Pacific Region, an estimated 10 million people in each region are chronically infected.

The highest burden of disease is in the Eastern Mediterranean Region and European Region, with 12 million people chronically infected in each region. Of those with chronic HCV infection, the risk of cirrhosis ranges from 15% to 30% within 20 years. The remaining 70% (55–85%) of persons will develop chronic HCV infection. Around 30% (15–45%) of infected persons spontaneously clear the virus within 6 months of infection without any treatment. Acute HCV infections are usually asymptomatic and most do not lead to a life-threatening disease. Hepatitis C virus (HCV) causes both acute and chronic infection.

There is currently no effective vaccine against hepatitis C.

Antiviral medicines can cure more than 95% of persons with hepatitis C infection, but access to diagnosis and treatment is low.

WHO estimated that in 2019, approximately 290 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).

There are an estimated 3.2 million adolescents and children with chronic hepatitis C infection.

Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.

The hepatitis C virus is a bloodborne virus and most infection occur through exposure to blood from unsafe injection practices, unsafe health care, unscreened blood transfusions, injection drug use and sexual practices that lead to exposure to blood.

The virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness to a serious, lifelong illness including liver cirrhosis and cancer.

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus.

Latest kontakt keygen